PD-L1 (TAP) >= 1%

About

Biomarker Type: Protein expression

Present: True

Marker: PD-L1

Unit: Tumor Area Positivity (TAP)

Equality: >=

Value: 0.01


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Fluorouracil, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Cisplatin, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Fluorouracil, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Cisplatin, Paclitaxel, Tislelizumab
FDA (1) PD-L1 (TAP) >= 1% Esophageal Squamous Cell Carcinoma Oxaliplatin, Paclitaxel, Tislelizumab
FDA (1) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (1) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab